CD14 and COVID-19: Given the observed proliferation of CD14+CD16+ intermediate monocytes in COVID-19 patients with severe pulmonary distress, it is possible that differential activation of Fcγ receptor subtypes, particularly FcγRIIA (inflammatory) and FcγRIIB (inhibitory), may contribute to an imbalanced inflammatory response.